Papadimitrakopoulou V, et al. IMPOWER132: PFS and safety results with 1L atezolimumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. IASLC 2018; abstract OA05.07.
Combinatie JAK-remmer en anti-PD-1 bij gemetastaseerd NSCLC
sep 2024 | Immuuntherapie, Longoncologie